Type 1 Diabetes Meal Dosing Intervention Study

Summary

Participation Requirements

Description

The long-term goal is to develop effective ways to improve glycemic control in youth with T1D. To that end, we propose to specifically evaluate the effectiveness, feasibility, and usability of two new interventions in diabetes care: an automated meal detection and patient engagement device to promot...

The long-term goal is to develop effective ways to improve glycemic control in youth with T1D. To that end, we propose to specifically evaluate the effectiveness, feasibility, and usability of two new interventions in diabetes care: an automated meal detection and patient engagement device to promote meal-time insulin dosing behavior (AIM2DOSE) and an economic incentive (COIN2DOSE) to promote patient engagement with mealtime insulin dosing behavior. If initially efficacious, our results will serve as the basis for an R01 submission(s) to conduct a fully powered efficacy trial of AIM2DOSE and COIN2DOSE. This study is significant as omission of mealtime boluses is one of the common reasons for suboptimal diabetes control in youth. This project is highly innovative because it will: 1) target youth who are predicted by artificial intelligence to experience a worsening in glycemic control, 2) use a just-in-time intervention to improve mealtime insulin dosing behavior, and 3) use an economic incentive intervention to improve mealtime insulin dosing behavior. Study Design The study is an unblinded, 3-arm, randomized, controlled trial. After successful screening and consent, individuals will wear a blinded Dexcom G6 Pro CGM inserted 1 week after consent. . At the baseline visit (visit 1; day 1), participants will be randomized to the AIM2DOSE, COIN2DOSE, or control treatment arms and will be trained on the procedures appropriate to their treatment arm. . Participants will also complete baseline measures by questionnaire. Participants will complete procedures specific to their treatment arm weekly. Visit 2 will occur after 12 weeks (90 days). Participants will stop any treatment interventions after this visit. A1C and questionnaire measures will be completed, and participants will again wear the Dexcom G6 Pro CGM for 10 days (the device will be returned by mail post-visit). Participants will receive no treatment intervention from week 13 to week 24. Participants will return for visit 3 at week 24. Again, A1C and questionnaire measures will be completed and participants will wear the Dexcom G6 Pro CGM for 10 days. All study participants will also have the option to participate in a focus group discussion (FGD) on general AI ethical issues (control group) or intervention experiences (intervention group). Parents of children who meet inclusion criteria may also elect to participate in a focus group. Study Visits Study visits may occur in-person or remotely (i.e., from home). Procedures will be adapted to accommodate both scenarios. Individuals who have been predicted via an artificial intelligence-intelligence based model to experience a rise in A1C in the near future (90 days) will be approached for recruitment. 36 participants will be recruited from the Children's Mercy Diabetes Center (any clinic or hospital location). Based on preliminary data review of our clinic population, there were at least 81 individuals who met inclusion criteria who were seen in clinic in the month of May 2019 alone. Patients will be randomized to AIM2DOSE, COIN2DOSE, or control group using a 1:1:1 randomization scheme. Intervention: To identify an at-risk population for more intensive intervention opportunities, the Children's Mercy Diabetes Center now routinely uses a validated prediction model based on advanced machine learning (random forest method) and natural language processing to identify individuals who are predicted experience a rise in A1C in the next 90 days. The model analyzes all patients who presented for a diabetes visit in the prior week. To accomplish this task, the complete health record for the CMH Diabetes Center registry is analyzed. We will select patients from this cohort for recruitment into the present study. AIM2DOSE intervention: The intervention consists of a Klue app that currently works with the Apple Watch. Users of the app must wear the watch on their dominant hand. The app constantly evaluates the movement of each participant's dominant hand by analyzing signals from the accelerometer and gyroscope in the device. By evaluating a real-time accelerometer and gyroscope data, the app can accurately identify repetitive movements that are consistent with eating. The software detects nearly 100% of meals within the first five minutes with very few false positives. Furthermore, the app correctly distinguishes between sips and bites 98% of the time. This novel use of a commonly available "health wearable" has not previously been reported as an adjunct to diabetes care in youth. COIN2DOSE intervention: From one-week post-randomization to the 12-week study visit, youth randomized to this treatment arm will receive personalized feedback via monetary incentives for dosing insulin at mealtimes. We will define mealtimes based on hour of the day and the presence of a carbohydrate entry associated with the insulin bolus. Breakfast will be 0600-1000, lunch will be 1100-1500, and dinner will be 1600-2000. Thus, we will reimburse youth per mealtime with at least one meal-associated (carbohydrate-associated) insulin bolus completed. We will offer the opportunity for youth to earn a bonus reimbursement for weeks during which they achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will pay youth per week for sharing their insulin use data at least two times per week with the study team during the three-month treatment phase.

Tracking Information